Management of disturbed calcium metabolism in uraemic patients: 1. Use of vitamin D metabolites

Nephrology Dialysis Transplantation

Volumn 15, Issue SUPPL. 5, 2000, Pages 18-24

  Schomig, M ^a   Ritz, E ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALFACALCIDOL; CALCIFEDIOL; CALCITRIOL; CALCITRIOL RECEPTOR; CALCIUM; COLECALCIFEROL; CREATININE; CYTOCHROME P450; DNA; ERGOCALCIFEROL DERIVATIVE; MESSENGER RNA; OXYGENASE; PARATHYROID HORMONE; PARATHYROID HORMONE RECEPTOR; PHOSPHATE; PHOSPHATE BINDING AGENT; VITAMIN D BINDING PROTEIN; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOTRANSFORMATION; CALCIUM METABOLISM; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DIALYSIS; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; DRUG INTOXICATION; DRUG SAFETY; HORMONAL REGULATION; HORMONE ACTION; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; KIDNEY CALCIFICATION; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; RAT; TREATMENT INDICATION; UREMIA; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM;

EID: 0033786216     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/15.suppl_5.18     Document Type: Article

References (73)

1. Expression of 25-hydroxyvitamin D3-1α-hydroxylase in the human kidney
2. 25-Hydroxyvitamin D3 metabolism in vitro by mononuclear cells from hemodialysis patients
3. Calcitriol, calcium, and granulomatous disease
4. Hypercalcemia in an anephric patient with sarcoidosis: Evidence for extrarenal generation of 1,25-dihydroxyvitamin D
5. Hypercalcemia and elevated calcitriol in a maintenance dialysis patient with tuberculosis
6. Regulation of intestinal vitamin D receptor expression in experimental uraemia: Effects of parathyroidectomy and administration of PTH
7. Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients
8. Secondary hyperparathyroidism and vitamin D receptor binding to vitamin D response elements in rats with incipient renal failure
9. Altered vitamin D metabolism and receptor interaction with the target genes in renal failure: Calcitriol receptor interaction with its target gene in renal failure
10. Inhibition of calcitriol receptor binding to vitamin D response elements by uremic toxins
11. Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients
12. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism
13. High phosphate level directly stimulates parathyroid hormone secretion and synthesis by human parathyroid tissue in vitro
14. Parathyroid cell proliferation in normal and chronic renal failure rats. The effects of calcium, phosphate, and vitamin D
15. 1α,25-Dihydroxy-vitamin D-3 regulates ATP-dependent calcium transport in basolateral plasma membranes of rat enterocytes
16. Skeletal response to intermittent calcitriol therapy in secondary hyperparathyroidism
17. 3 effects in primary cultures of growth cartilage cells of the rat
18. 3 have different effects on growth plate chondrocytes in vitro
19. Immunological evidences for the presence of small late carboxylterminal fragment(s) of human parathyroid hormone (PTH) in circulation in man
20. Immunochemiluminometric assay with two monoclonal antibodies against the N-terminal sequence of human parathyroid hormone
21. A novel mechanism for skeletal resistance in uremia
22. Identification of risk factors on secondary hyperparathyroidism undergoing long-term haemodialysis with vitamin D3
23. Differences in vitamin D status between countries in young adults and the elderly
24. Serum vitamin D concentrations among elderly people in Europe
25. Hypovitaminosis D in medical inpatients
26. How important is vitamin D deficiency in uraemia?
27. 25-Hydroxycholecalciferol stimulation of muscle metabolism
28. The effect of 25-hydroxy vitamin D3 in the osteomalacia of chronic renal failure
29. Plasma 25-hydroxycholecalciferol in chronic renal failure
30. Is low plasma 25-(OH) vitamin D a major risk factor for hyperparathyroidism and Looser's zones independent of calcitriol?
31. Comparison of 1α-hydroxycholecalciferol and 25-hydroxycholecalciferol in the treatment of renal osteodystrophy: Greater effect of 25-hydroxycholecalciferol on bone mineralization
32. Kinetics of serum 1,84 iPTH after high dose of calcitriol in uremic patients
33. Intermittent versus continuous administration of 1,25-dihydroxyvitamin D3 in experimental renal hyperparathyroidism
34. Vitamin D therapy in patients receiving dialysis
35. Effect of the mode of calcitriol administration on PTH-ionized calcium relationship in uraemic patients with secondary hyperparathyroidism
36. 'Pulse' oral calcitriol in uraemic patients: Rapid modification of parathyroid response to calcium
37. The 'oral 1,25-dihydroxyvitamin D3 pulse therapy' in hemodialysis patients with severe secondary hyperparathyroidism
38. Treatment of severe secondary hyperparathyroidism with administration of calcium carbonate, intermittent high oral doses of 1,25-dihydroxyvitamin D3 and dialysate with 3 mEq/1 calcium concentration
39. Suppression of secondary hyperparathyroidism in chronic dialysis patients by single oral weekly dose of 1,25-dihydroxycholecalciferol
40. Comparison of intermittent and continuous oral administration of calcitriol in dialysis patients: A randomized prospective trial
41. Daily but not pulse calcitriol therapy improves growth in experimental uremia
42. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients
43. Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patients. Italian group for the study of intravenous calcitriol
44. Effective treatment of secondary hyperparathyroidism in hemodialysis patients by titration of intravenous calcitriol dosage
45. Comparison of intermittent oral and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism
46. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD
47. What stimuli control the activity of the parathyroid cell?
48. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure
49. Intermittent oral 1α-hydroxyvitamin D2 is effective and safe for the suppression of secondary hyperparathyroidism in haemodialysis patients. 1αD2 study group
50. A comparison of oral and intravenous alphacalcidol in the treatment of uremic hyperparathyroidism
51. Regulation of vitamin D action
52. 3 and 22-oxacalcitriol on phosphate and calcium metabolism
53. Effect of 22-oxacalcitriol on calcium metabolism in rats with severe hyperparathyroidism
54. The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion
55. Regulation of parathyroid hormone synthesis in chronic renal failure in rats
56. 3, on bone mineral metabolism in normal male rats
57. 22-Oxacalcitriol ameliorates high-turnover bone and marked osteitis fibrosa in rats with slowly progressive nephritis
58. 3 on bone metabolism in young X-linked hypophosphatemic male mice
59. 22-Oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure
60. Effect of 22-oxacalcitriol on hyperparathyroidism of dialysis patients: Results of a preliminary study
61. Effect of 22-oxacalcitriol on bone histology of hemodialyzed patients with severe secondary hyperparathyroidism
62. 19-Nor-1α-25-dihydroxyvitamin D2 (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis
63. PTH/PTHrP receptor mRNA is down-regulated in epiphyseal cartilage growth plate of uraemic rats
64. Comparison of intact, midregion, and carboxy terminal assays of parathyroid hormone for the diagnosis of bone disease in hemodialyzed patients
65. Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia
66. Calcium carbonate, an aluminum-free agent for control of hyperphosphatemia, hypocalcemia, and hyperparathyroidism in uremia
67. Low-dose calcitriol prevents the rise in 1,84-iPTH without affecting serum calcium and phosphate in patients with moderate renal failure (prospective placebo-controlled multicentre trial)
68. The effect of long-term intravenous calcitriol administration on parathyroid function in hemodialysis patients
69. Is intermittent oral calcitriol safe and effective in renal secondary hyperparathyroidism?
70. Hyperphosphataemia a silent killer of patients with renal failure?
71. Calcium kinetics and the long-term effects of lowering dialysate calcium concentration
72. Phosphate binders on iron basis: A new perspective?
73. Control of serum phosphate without any phosphate binders in patients treated with nocturnal hemodialysis